News archive

December 20, 2021
Development and preparations for first-in-human pilot study is on track as Lifecare successfully has manufactured nanogranular tunneling strain (NTR) sensors on the prototype Sencell electrodes at the new Lifecare NanoBioSensors laboratory. The manufacturing of NTR sensors is a major technical achievement for Lifecare. On the operational side, the Lifecare Board of Directors has approved the Share […]
Read more
October 14, 2021
Lifecare has been invited to take seat in the Industrial Advisory Board (IAB) at the 5th International Conference on Manipulation, Automation and Robotics at Small Scales (MARSS) to be held in Toronto, Canada, Jul 18-22, 2022. Lifecare has accepted the invitation.   MARSS is the flagship event for cross-disciplinary R&D communities to discuss current activities […]
Read more
October 12, 2021
Lifecare has successfully completed a private placement issuing new shares providing the company with NOK 26,3 million in gross proceeds. The price per offer share was set at market to NOK 1,70. The Lifecare Nanobiosensors MEMS & Sensor Research Laboratory in Reutingen (DE) is now operational and Lifecare has engaged Cambridge Consultants in Cambridge (UK) […]
Read more
September 2, 2021
Lifecare’s activities in the period after the shareholder letter distributed July 2nd, 2021 have been focused on streamlining the continued development of the Sencell technology and to continue to ensure organizational adjustments with the aim to optimize the R&D set-up. In addition, the Board and administration of Lifecare have focused on financial preparations ensuring operational […]
Read more
September 1, 2021
Lifecare AS (lifecare.no) is a listed Norwegian company with operations in Germany (Rhine-Main Area). The company is engaged in the development of innovative biosensors based on MEMS and NEMS technologies. The current flagship product is a very small implantable continuous glucose sensor with ultra-long duration of use for patients with Diabetes mellitus. Lifecare is currently […]
Read more
August 27, 2021
Lifecare has signed a term sheet to acquire the laboratory of Pfützner Science & Health Institute GmbH (the “Lab”) for a total consideration of up to Euro 1.175 million of which Euro 100,000 will be paid in cash, Euro 300,000 will be settled in new shares in Lifecare, and the remaining part of the consideration, […]
Read more
August 27, 2021
The Board of Directors (the “Board”) of Lifecare AS (the “Company” or “Lifecare”) has passed a resolution convening an Extraordinary General Meeting to be held on 10 September 2021 to approve a board authorization for a share capital increase of up to 25% of the Company’s current share capital (the “Board Authorisation”). ‍ Lifecare has engaged Carnegie […]
Read more
August 3, 2021
The European Patent Office (EPO) has as expected decided to grant Lifecare a new patent for an updated sensor measuring system. The now approved patent expands Lifecare’s protection in time and scope.   As announced in Lifecare’s press release 25.03.21, the EPO by then intended to grant this patent, about an “interstitial fluid osmotic pressure […]
Read more
July 2, 2021
The spring and early summer has been busy in Lifecare. In addition to continued development of the Sencell technology, the activity during this period has included preparation and implementation of necessary organizational adjustments, including clarifications and negotiations related to Digital Diagnostics AG and the acquisition of Cantimed UG.   Lifecare’s annual general meeting was held […]
Read more